21 slides from Expres2ion Biotech Holding Ab's earnings presentation, Nov 17, 2022
Slide 1: Q3 2022 Financial Report
ExpreS2ion Biotech Holding AB Q3 2022 Financial Report Proteins for Life 17th November 2022 H C Andersen Capital Webinar Bent U. Frandsen, CEO Keith Alexander, CFO
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights Vaccine development platform with track re
Slide 4: Management Team
Management Team >200 years of professional skills and experience from the life sciences industry Management Board of Directors • Bent U. Frandsen, Chief Executive Officer • Dr. Martin R. Jensen, Chairman & Co-founder • Keith Alexander, Chief Financial Officer • Jakob Knudsen, Member of the Board • D
Slide 5: New Scientific Advisory Board
New Scientific Advisory Board Key Opinion Leaders (KOLs) providing clinical advise on our oncology development programme Dr. Giuseppe Curigliano, MD, PhD Dr. Ulrik Lassen, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Professor at University of Copenhagen, Depar
Slide 6: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Market Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Potential Pharmacology >€30 billion1 Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II Ph. III initiated PREVENT-nCoV Progr
Slide 7: Breast Cancer
BREAST CANCER The Most Common Cancer 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime ~25% have overexpression of HER2 receptors, associated with more aggressive tumors and reduced survival2 685,000 deaths worldwide in 2020 due to breast cancer1 Proteins for Life 1. Breast
Slide 8: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 9: Unique Technology Platforms
BREAST CANCER Unique Technology Platforms Our HER2 vaccine ES2B-C001 combines a highly immunogenic antigen with unique presentation technology ExpreS2 platform Particle (VLP) technology - Combines S2 cells with - AdaptVac’s proprietary virus- patented expression vectors like particles (VLP) technolo
Slide 10: New Publication Supports ES2B-C001
BREAST CANCER New Publication Supports ES2B-C001 Preclinical Proof-of-Concept Proteins for Life Reference: F. Ruzzi et al (2022): “Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine”, Biomedicines. https://www.mdpi.com/2227-9059/10/
Slide 11: Progression as Planned
BREAST CANCER Progression as Planned Important steps as ES2B-C001 is moving closer to the planned clinical Phase I trial in 2024 • GMP Manufacturing ✓ GMP (Good Manufacturing Practice) Manufacturers selected and Work Order Statements executed ✓ ExpreS2ion’s processes for manufacturing of material fo
Slide 12: ABNCoV2 COVID-19 Vaccine
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Bavarian Nordic completed the Phase II study, and initiated the Phase III study Phase II results confirms ABNCoV2 as universal booster Phase III study initiated in USA and Europe • Evaluation as a booster vaccine in ~100 individuals with existing • 4,000 previous
Slide 13: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 14: Operating Income
FINANCE Operating Income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6.000 6.000 6.000 Net sales Other operating income 5.000 5.000 5.000 = + 4.000 4.000 4.000 3.000 3.000 3.000 2.000 2.000 2.000 1.000 1.000 1.000 0 0 0 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q20 3Q20 1
Slide 15: Operating Costs
FINANCE Operating Costs Operating costs, SEK ‘000s R&D costs (external), SEK ‘000s 0 0 -8.000 -5.000 -16.000 -10.000 -24.000 -15.000 -32.000 -20.000 -40.000 -25.000 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 Proteins for Life 15
Slide 16: Profit / Loss for the Period
FINANCE Profit / Loss for the Period 3Q profit / loss, SEK ‘000s Year-to-date profit / loss, SEK ‘000s 2021 2022 2021 2022 0 0 -7.000 -15.000 -9.382 -14.000 -30.000 -29.605 +227% -21.000 -45.000 +137% -28.000 -60.000 -30.701 -70.072 -35.000 -75.000 Proteins for Life 16
Slide 17: Cash Development Year-to-Date
FINANCE Cash Development Year-to-Date SEK millions 250 62 200 9 150 150 139 -60 100 50 0 December 2021 New Capital Operations and Investment Activities Currency changes September 2022 Note: December cash and cash flow from investing activities adjusted for impact if temporarily storing cash in the C
Slide 18: Cash Balance, 2019-2022 Quarterly
FINANCE 1 Cash Balance , 2019-2022 Quarterly SEK millions 180 168 160 150 142 139 140 125 120 107 108 100 83 80 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 1 For Q4 2021 and Q1 2022, the cash balance combines funds on the Company’s SKAT acco
Slide 19: Shareholder Composition
FINANCE Shareholder Composition ~13,000 shareholders holding ~37.6 million shares No. of shareholders, No. of shares outstanding including brokers 16.000 40.000.000 14.000 35.000.000 12.000 30.000.000 10.000 25.000.000 8.000 20.000.000 6.000 15.000.000 4.000 10.000.000 2.000 5.000.000 0 0 3Q19 4Q19
Slide 20: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 BN Phase III initial readout in CORONAVIRUS (ABNCoV2) early 2023 BN Phase II BN Phase II BN Phase III BN initiating rolling submission study initiation study readout study initiation Q3 21 H1 2022 Q3 2022 BN ready for market launch (subject to regulator
Slide 21: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life